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• Split-thickness skin grafting & acellular treatment have 
complications including overgrafting, hypertrophic scarring 
and pigmentation changes in burn patients.
• Cellutome™️ blister grafts may aid in re-pigmentation, 
minimized donor site, decreased hypertrophic scarring, and 
minimized pain.
• Vancouver Scar Scale (most widely used scar evaluation 
scale 1-15 but not sensitive enough for this study)
– Readings at a max of 2/15 with normal vascularity, 
pliability, and height, and 2 patients showing mixed 
pigmentation in skin sites. 
• Treatment site healed with less complications and 
pigmentation changes than the acellular site according to 
observation. 
• The Patient Observer Scar Scale (more reliable scars scale 
1-10) 
– Readings showed Cellutome™️ blister graft patients to 
have pain and stiffness reaching a maximum of 2/10, 
itching reaching a maximum of 3/10, scar coloring at a 
maximum of 5/10, and thickness at a maximum of 
4/10.
• P-Value shows the findings to be statistically insignificant, 
observations showed that the Cellutome™️ blister graft site 
healed better than the acellular site.  
• Prospective controlled study comparing acellular to cellular 
technique in 2nd degree burn wound healing. 
• IRB approval and informed consent obtained.
• Cellutome™️ harvester creates small blisters which are cut 
and adhered to transfer medium which is applied to the 
treatment site.
• SuprathelⓇ temporary skin substitute used as dressing until 
healing.
• Donor site covered with silicone tape.
• Follow-up data was obtained up to 1 year +/- 6months post-
treatment
• Days until healing, pigmentation, sensation, Vancouver Scar 
Scale and POSAS recorded. 
• The Cellutome™️ blister grafts met the first endpoint of this 
study 
– Healing time of 18 days or less (faster than the 
acellular control site) 
• Microscopic donor sites did not bother the patients.
• Treatment site had sensation and appearance comparable to 
that of healthy skin (second study endpoint)
• Cellutome™️ blister grafts should be further explored as: 
– An effective and efficient method of epidermal skin 
grafting 
– Having a low rate of complication and a high rate of 
satisfaction
– An alternative to acellular treatment in 2nd degree 
(partial thickness) burn patients to avoid pigment 
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Purpose
Determine if:
1. Healing occurs faster than acellular treatment (within 21 
days of treatment) in 2nd degree burn wounds
2. Pigment changes are decreased using Cellutome™️ blister 
grafts.
3. Donor site is not noticeable with this technique.
Figure 2








Treatment to Healthy P value of E 
value 0.909390143
Acellular to healthy of P value to E 
value 0.891612179
Treatment to healthy of P value of 
M value 0.868449035
Acellular to healthy of P value to 
M value 0.99937299
Treatment to acellular P value of E 
value 0.978344712




























Semmes-Weinstein P Values for:
treatment to healthy 0.553061265
control to healthy 0.254654276
treatment to control 0.6350855
Difference between treatment and 
control P values 0.298406989
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All of the patients in this study showed a 100% treatment success rate with no 
infection, failed grafts, or STSG needed.
1. The Semmes-Weinstein Scale should not have different readings since nerve 
endings were not damaged. Filaments in the test may have missed nerves on 
some of the readings due to location.
2. The P-Values do not show statistical significance, but this is due to the small 
data set. Few patients are willing to return to the office for additional checkups 
throughout the study. Patients had a faster healing and less pigmented scar with 
no donor site using Cellutome™️ blister grafting. 
The A site received Cellutome™️ blister grafts and the B site received acellular treatment. Notice the small 
dots of pigmentation on the healed A site. These will continue to regenerate pigmented skin cells as the skin 
heals to give the A site an appearance closer to that of the surrounding healthy skin.  
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Figure 3 and 4 show the erythema and melanin levels in the skin sites after Cellutome™️ blister 
grafting. The treatment site shows less variation from the  healthy site than the acellular site. 
